ALLK | tickerfilter.com

Fundamental analysis

33%

Profitability 35%

Dept financing 25%

Liquidity 50%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

28.76%

2 Year

-77.15%

Key data

Stock price

$0.33

P/E Ratio

0.00

DAY RANGE

$0.33 - $0.33

EPS

-$0.78

52 WEEK RANGE

$0.22 - $0.33

52 WEEK CHANGE

$26.53

MARKET CAP

20.530 M

YIELD

N/A

SHARES OUTSTANDING

90.377 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.64

PUBLIC FLOAT

AVERAGE 10 VOLUME

N/A

AVERAGE 30 VOLUME

N/A

Company detail

CEO: Robert Alexander
Region: US
Website: allakos.com
Employees: 190
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Allakos Inc. develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of gastritis and/or eosinophilic duodenitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria.

ALLK - Allakos Inc.